Michael Wolff was at the "edge of a cliff" when he was diagnosed with a cancer that affects less than 300 patients a year in the U.S.

When Michelle Gidion first noticed the blue bruises dotted across her lower legs, she put them down to the family dog bashing ...

A report's revelation that some popular brands contain cancer-causing chemicals has confirmed suspicions about oversights in ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

Waksal, who is not a medical doctor, imported the veterinary drug along with other “unapproved ingredients” from Colombia.

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Merck (NYSE:MRK) shares inched higher on Friday after Summit Therapeutics (NASDAQ:SMMT) announced the latest survival data ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Survey results revealed a widespread - and often misguided - belief that subcutaneous delivery volumes must be limited to 3 ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Sharon’s cancer diagnosis was completely unexpected. She had no symptoms when she was invited to a routine breast screening ...